

1 **Supplementary information**

2  
3 **Dual-ligand modified liposomes provide effective local targeted**  
4 **delivery of lung-cancer drug by antibody and tumor lineage-homing**  
5 **cell-penetrating peptide**

6  
7 **Congcong Lin<sup>1</sup>, Xue Zhang<sup>1</sup>, Hubiao Chen<sup>1</sup>, Zhaoxiang Bian<sup>1</sup>, Ge Zhang<sup>1</sup>,**  
8 **Muhammad Kashif Riaz<sup>1</sup>, Deependra Tyagi<sup>1</sup>, Ge Lin<sup>3</sup>, Yanbo Zhang<sup>4</sup>, Jinjin**  
9 **Wang<sup>2</sup>, Aiping Lu<sup>1,2\*</sup>, Zhijun Yang<sup>1,2 \*</sup>**

10  
11 <sup>1</sup>School of Chinese Medicine, Hong Kong Baptist University, 7 Baptist University Road, Kowloon Tong, Hong  
12 Kong, China

13 <sup>2</sup>Changshu Research Institute, Hong Kong Baptist University, Changshu Economic and Technological  
14 Development (CETD) Zone, Changshu 215500, China

15 <sup>3</sup>School of Biomedical Sciences, Chinese University of Hong Kong, Area 39, CUHK, Shatin, NT, Hong Kong,  
16 China

17 <sup>4</sup>School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road,  
18 Pokfulam, Hong Kong, China

19 \*Corresponding author.

20 Correspondence and requests for materials should be addressed to Z.Y. (email: yzhijun@hkbu.edu.hk; Tel.:  
21 +852-3411-2961; fax: +852-34112461)

22

### 23 **Cellular uptake study**

24 A549 cells, a human non-small cell lung cancer cell line and MRC-5, a human lung  
25 fibroblast cell line were seeded to confocal dish and allowed to incubate for 24 h at a  
26 density of  $1 \times 10^5$  cells per well. Then, cells were incubated with NBD-DPPE labeled  
27 CPP33-lip and lip (final NBD-DPPE concentration  $4 \mu\text{g/mL}$ ) for 4 h at  $37^\circ\text{C}$ . 30 min  
28 before the end of the treatment, LysoTracker Red (50 nM) was added to stain the  
29 lysosomes. The cells were washed three times with PBS, followed by fixation with 4%  
30 paraformaldehyde for 15 min. The nuclei were stained with Hoechst 33342 ( $2.5$   
31  $\mu\text{g/mL}$ ) for 15 min at  $37^\circ\text{C}$ . Finally, the cells were washed another three times with  
32 PBS and visualized by confocal laser scanning microscope (CLSM).

### 33 **Detection of CA IX expression in cell cultures**

34 A549 cells were exposed to normoxia (humidified air with 5%  $\text{CO}_2$ ) or hypoxia (in a  
35 Modular Incubator Chamber purged with 1%  $\text{O}_2$ , 5%  $\text{CO}_2$  and 94%  $\text{N}_2$ ) at  $37^\circ\text{C}$  for 20 h,  
36 followed by CA IX detection by Western blot. The samples were denatured with  
37 loading buffer and 20  $\mu\text{L}$  of each sample was loaded into 8% SDS-PAGE gels under  
38 reducing conditions, then electrotransferred to a polyvinylidene difluoride (PVDF)  
39 membranes. The blots were blocked with 5% nonfat milk for 1 h, followed by  
40 incubation with anti-CA IX primary antibody overnight at  $4^\circ\text{C}$ . Then the membrane  
41 was incubated with the goat anti-rabbit HRP-conjugated secondary antibody at room  
42 temperature for 1 h. A SuperSignal West Pico Chemiluminescent Substrate (Thermo  
43 Fisher Scientific) was used for HRP-based detection of the anti-CA IX antibody.

### 44 **Analytical method for pharmacokinetics study**


45 Hydrocortisone was added (50  $\mu\text{L}$ , 200  $\text{ng/mL}$ ) as an internal standard (IS) to 0.2  
46 mL of plasma. The samples were mixed, and extracted with ethyl acetate (750  $\mu\text{L}$ )  
47 followed by vortexing for 4min and centrifuging for 10min at 8000 rpm. The upper  
48 organic phase was carefully transferred and evaporated to dryness in vacuum. The  
49 residues were dissolved in 100 $\mu\text{L}$  methanol and centrifuged at 4000rpm for 10 min,  
50 then the supernatant was collected and injected into the Agilent 1290 Ultra High

51 Performance Liquid Chromatograph with Agilent 6460 Triple Quadrupole Mass  
52 Spectrometer system (UHPLC-QQQ MS/MS).


53 Chromatography conditions: Waters Acquity BEH C18 (2.1 ×50 mm); Mobile phase  
54 0.1% formic acid in water: 0.1% formic acid in acetonitrile =80:20 v/v; Flow rate 0.35  
55 mL/min; Running time 10 min.

56 Mass spectrometer conditions: Ion Source Agilent Jet Stream electro spray  
57 ionization (AJS ESI); Positive mode; Gas Temperature 300 °C; Gas flow rate 8 L/min;  
58 Nebulizer 40 psi; SheathGasHeater 350 °C; SheathGasFlow 8 L/min; Capillary 3500  
59 V; VCharging 1000 V.

60 Firstly, optimization of mass spectrometry was initiated by automatic tuning of the  
61 instrument (Figure S1). Method validation was conducted before the sample analysis.  
62 The specificity of the established method was assessed by comparing the  
63 chromatograms of blank plasma, blank plasma with TPL, blank plasma with IS, and  
64 plasma after endotracheal administration (Figure S2). The calibration curve in rat  
65 plasma was linear over the ranges 10-2500 ng/mL in rat plasma ( $y=0.375035x +$   
66  $0.025498$ ,  $R^2=0.9946$ ). The extraction recoveries were higher than 90%, while  
67 accuracy and precision both intra-day and inter-day were less than 10%. The method  
68 was sufficiently accurate and consistent for proceeding for the biological analysis of  
69 TPL (Table S1). Therefore, the established method was applied to the analysis of rat  
70 plasma samples.



**Fig. S1.** Mass spectra of (a) TPL and (b) IS (Hydrocortisone).



**Fig. S2.** Representative MRM chromatograms of TPL ( I ) and IS ( II ). (a) blank plasma, (b) blank plasma spiked with TPL and IS, (c) plasma sample after endotracheal administration of 5 min with a dose of 0.5 mg/kg.


78 **Table S1.** Extraction recovery, accuracy and precision data of TPL in plasma (n=5).

Concentration (ng/mL)	Extraction recovery% (mean ± SD)	Accuracy (RE%)		Precision (RSD%)	
		Intra-day	Inter-day	Intra-day	Inter-day
20	96.07 ± 5.61	0.73	0.25	9.55	5.61
313	95.16 ± 6.52	0.58	0.47	8.33	7.82
2500	94.72 ± 3.17	0.70	0.55	9.90	8.33

79

80 **Relationship of cell number with radiance**

81 Luciferase gene transduced cell line (A549-Red-Fluc) was used to create an  
 82 orthotopic lung tumor bearing model by intrathoracic injection. The relationship of  
 83 cell number with radiance was firstly determined *in vitro* before inoculating into the  
 84 mice. A549-Red-Fluc cells were cultured in Dulbecco's modified Eagle's medium  
 85 (DMEM) with GlutaMAX supplemented with 10% fetal bovine serum, 100 U/mL  
 86 penicillin, and 100 µg/mL streptomycin. The cells were seeded at a density of  $1 \times 10^6$   
 87 into a T75 flask, and grown for 2 days. Thereafter, the cells were trypsinized and  
 88 collected. Cells were pelleted by centrifuging at 1000 rpm for 5 min; the old medium  
 89 was removed. Cells were washed and resuspended with PBS. 100 µL of various  
 90 numbers of cells (0, 1.562, 3.125, 6.25, 12.5, 25, 50, 100  $\times 10^4$ ) were transferred into  
 91 black 96-well plates. For luciferase expression, 100 µL of D-luciferin was added into  
 92 each well. The luminescence signal was determined by the IVIS Lumina XR system  
 93 (Caliper Life Sciences) (Figure S3) .




94

95

96

97 **Pulmonary administration of the drug**

98 For endotracheal administration, the mouse was firstly anesthetized with 5% of  
 99 chloral hydrate at a dose of 300 mg/kg by intraperitoneal injection. Then the mice  
 100 were placed in a neck vertical position. The tongue of mouse was gently pulled out  
 101 with tweezers. A small transparent tube was inserted under the tongue to the trachea of  
 102 mouse. The treatment formulations were sprayed to the trachea using Microsprayer®  
 103 Aerosolizer Pulmonary Aerosol kit for Mouse Model PAK-MSA (Penn-Century, Inc.  
 104 Wyndmoor, PA19038 USA) (Figure S4) .



105

106 **Fig. S4.** Illustration for endotracheal administration. (a) Microsprayer® Aerosolizer Pulmonary  
107 Aerosol kit for Mouse Model PAK-MSA; (b) Endotracheal administration to the nude mouse.

108

109